Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 352

1.

Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.

Sengupta S, Schiff R, Katzenellenbogen BS.

Breast Cancer Res Treat. 2009 Sep;117(2):243-51. doi: 10.1007/s10549-008-0186-z. Epub 2008 Sep 19.

2.

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.

PMID:
15199112
3.

Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

Kurokawa H, Arteaga CL.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Review.

PMID:
11916237
4.

Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.

Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE.

Mol Cancer Res. 2007 Jan;5(1):71-85.

5.

Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.

Brennan K, McSherry EA, Hudson L, Kay EW, Hill AD, Young LS, Hopkins AM.

Oncogene. 2013 May 30;32(22):2799-804. doi: 10.1038/onc.2012.276. Epub 2012 Jul 2.

PMID:
22751120
6.

The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.

Thaler S, Thiede G, Hengstler JG, Schad A, Schmidt M, Sleeman JP.

Int J Cancer. 2015 Aug 1;137(3):686-97. doi: 10.1002/ijc.29404. Epub 2015 Jan 8.

7.

Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.

Yanai A, Inoue N, Yagi T, Nishimukai A, Miyagawa Y, Murase K, Imamura M, Enomoto Y, Takatsuka Y, Watanabe T, Hirota S, Sasa M, Katagiri T, Miyoshi Y.

Clin Breast Cancer. 2015 Jun;15(3):197-203. doi: 10.1016/j.clbc.2014.12.002. Epub 2014 Dec 24.

PMID:
25600244
8.
9.

Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.

Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB, Stoica A.

Oncogene. 2003 Sep 11;22(39):7998-8011.

PMID:
12970748
10.

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.

Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T.

Breast Cancer Res. 2008;10(6):R101. doi: 10.1186/bcr2204. Epub 2008 Dec 3.

11.

Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.

Fan P, McDaniel RE, Kim HR, Clagett D, Haddad B, Jordan VC.

Eur J Cancer. 2012 Dec;48(18):3488-98. doi: 10.1016/j.ejca.2012.04.020. Epub 2012 Jun 2.

12.

Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.

Chen G, Chen SM, Wang X, Ding XF, Ding J, Meng LH.

J Biol Chem. 2012 Apr 6;287(15):12132-41. doi: 10.1074/jbc.M111.302299. Epub 2012 Feb 15. Erratum in: J Biol Chem. 2012 Jun 1;287(23):19336.

14.

Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.

Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J, van de Water B.

Breast Cancer Res. 2011 May 19;13(3):R52. doi: 10.1186/bcr2883.

15.

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.

Lindberg K, Helguero LA, Omoto Y, Gustafsson JÅ, Haldosén LA.

Breast Cancer Res. 2011 Apr 14;13(2):R43. doi: 10.1186/bcr2865.

16.

Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.

Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A.

PLoS One. 2010 Feb 2;5(2):e9024. doi: 10.1371/journal.pone.0009024.

17.

Estradiol rapidly activates Akt via the ErbB2 signaling pathway.

Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB, Stoica A.

Mol Endocrinol. 2003 May;17(5):818-30. Epub 2003 Jan 23. Retraction in: Mol Endocrinol. 2004 Aug;18(8):2096.

PMID:
12554767
18.
19.

PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.

Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A.

Cell Signal. 2010 Sep;22(9):1369-78. doi: 10.1016/j.cellsig.2010.05.006. Epub 2010 May 12.

20.

Pomolic acid inhibits metastasis of HER2 overexpressing breast cancer cells through inactivation of the ERK pathway.

Kim B, Kim YC, Park B.

Int J Oncol. 2016 Aug;49(2):744-52. doi: 10.3892/ijo.2016.3568. Epub 2016 Jun 7.

PMID:
27277173

Supplemental Content

Support Center